IMR Press / FBL / Volume 13 / Issue 1 / DOI: 10.2741/2662

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Insulin-like growth factor-1 in plasma and brain: regulation in health and disease
Show Less
1 Max-Planck-Institute of Psychiatry, Kraepelinstr, 2-10, 80804 Munich

Academic Editor: Akihiko Wada

Front. Biosci. (Landmark Ed) 2008, 13(1), 85–99;
Published: 1 January 2008
(This article belongs to the Special Issue Insulin and insulin-like growth factor-1 signalings in neuronal cells)

IGF-1 was first described as a growth mediating factor regulated in the context of the somatotrophic axis. During the last decade, it has gained much attention for its role in the regulation of lifespan, brain function, cell growth, and metabolism. Associations of plasma IGF-1 levels in physiological and pathological conditions such as aging, cardiovascular disease, metabolic disorders, dementia, and neurodegenerative disorders, and its potential as a neurotrophic agent, have been intensively studied. Acromegaly due to jGH and IGF-1 excess and growth hormone deficiency with decreased GH and IGF-1 might serve as models to study IGF-1 function, but the effects of GH and IGF-1 in these conditions are often indistinguishable. Due to this overlap, this article will only briefly mention pathophysiological implications in acromegaly and growth hormone deficiency. It will focus on IGF-1 and give an overview of the vast literature on the role and regulation of IGF-1 in plasma and brain, its alteration in health and disease and its possible therapeutical applications.

Back to top